ISOFOL MEDICAL HAS SUCCESSFULLY ADVANCED TO THE NEXT DOSE LEVEL OF MODUFOLIN® IN A PHASE I/II CLINICAL TRIAL IN COLORECTAL CANCER.
Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with 5-FU and oxaliplatin or 5-FU and irinotecan, in the ongoing, incremental dose cohort, phase I/II clinical trial, ISO-CC-005. In total 16 patients with stage IV colorectal cancer have successfully completed their treatment with Modufolin® at 30 mg/m2. Isofol has now initiated a second dose level of Modufolin®, 60mg/m2, in combination with 5-FU and oxaliplatin or 5-FU and irinotecan. This is a safety study evaluating four different doses of Modufolin® with the intention to identify the dose